B cells secrete eotaxin-1 in human inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 19, Issue 5, 2013, Pages 922-933

  Rehman, Mian Qasim ^a   Beal, Dominic ^a   Liang, Yan Mei ^a   Noronha, Ansu ^b   Winter, Harland ^c   Farraye, Francis A ^b   Ganley Leal, Lisa ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON MEDICAL CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

B cell; Eosinophil; Eotaxin 1; Inflammatory bowel disease

Indexed keywords

CHEMOKINE RECEPTOR CCR10; CHEMOKINE RECEPTOR CCR9; EOTAXIN; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4;

ADOLESCENT; ADULT; ARTICLE; B LYMPHOCYTE; BLOOD FLOW; BLOOD SAMPLING; CELL ACTIVATION; CELL HOMING; CELL ISOLATION; CELL MIGRATION; CELL STIMULATION; CHEMOTAXIS; CHILD; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ACTIVITY; ENTERITIS; EOSINOPHIL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INTESTINE MUCOSA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SCHOOL CHILD; ULCERATIVE COLITIS;

ADOLESCENT; B-LYMPHOCYTES; CASE-CONTROL STUDIES; CELLS, CULTURED; CHEMOKINE CCL11; CHEMOTAXIS; CHILD; COHORT STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; CYTOKINES; EOSINOPHILS; HUMANS; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; QUESTIONNAIRES; TOLL-LIKE RECEPTORS;

EID: 84876365525     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e3182802950     Document Type: Article

References (61)

1. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology. 2004; 126:1504-1517.
2. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007;369:1627-1640.
3. Basset C, Holton J. Inflammatory bowel disease: is the intestine a Trojan horse? Sci Prog. 2002;85:33-56.
4. Baumgart DC, Thomas S, Przesdzing I, et al. Exaggerated inflammatory response of primary human myeloid dendritic cells to lipopolysaccharide in patients with inflammatory bowel disease. Clin Exp Immunol. 2009; 157:423-436.
5. Noronha AM, Liang Y, Hetzel JT, et al. Hyperactivated B cells in human inflammatory bowel disease. J Leukoc Biol. 2009;86:1007-1016.
6. Monteleone G, Caprioli F. T-cell-directed therapies in inflammatory bowel diseases. Clin Sci (Lond). 2010;118:707-715.
7. Henderson P, van Limbergen JE, Schwarze J, et al. Function of the intestinal epithelium and its dysregulation in inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:382-395.
8. Woodruff SA, Masterson JC, Fillon S, et al. Role of eosinophils in inflammatory bowel and gastrointestinal diseases. J Pediatr Gastroenterol Nutr. 2011;52:650-661.
9. Brandtzaeg P, Carlsen HS, Halstensen TS. The B-cell system in inflammatory bowel disease. Adv Exp Med Biol. 2006;579:149-167.
10. McDonnell M, Liang Y, Noronha A, et al. Systemic toll-like receptor ligands modify B-cell responses in human inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:298-307.
11. Forssmann U, Uguccioni M, Loetscher P, et al. Eotaxin-2, a novel CC chemokine that is selective for the chemokine receptor CCR3, and acts like eotaxin on human eosinophil and basophil leukocytes. J Exp Med. 1997;185:2171-2176.
12. Kitaura M, Suzuki N, Imai T, et al. Molecular cloning of a novel human CC chemokine (Eotaxin-3) that is a functional ligand of CC chemokine receptor 3. J Biol Chem. 1999;274:27975-27980.
13. Garcia-Zepeda EA, Rothenberg ME, Ownbey RT, et al. Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nat Med. 1996;2:449-456.
14. Rothenberg ME, Mishra A, Brandt EB, et al. Gastrointestinal eosinophils. Immunol Rev. 2001;179:139-155.
15. Akuthota P, Wang HB, Spencer LA, et al. Immunoregulatory roles of eosinophils: a new look at a familiar cell. Clin Exp Allergy. 2008;38: 1254-1263.
16. Manousou P, Kolios G, Valatas V, et al. Increased expression of chemokine receptor CCR3 and its ligands in ulcerative colitis: the role of colonic epithelial cells in in vitro studies. Clin Exp Immunol. 2010;162:337-347.
17. Ahrens R, Waddell A, Seidu L, et al. Intestinal macrophage/epithelial cellderived CCL11/eotaxin-1 mediates eosinophil recruitment and function in pediatric ulcerative colitis. J Immunol. 2008;181:7390-7399.
18. Irvine EJ. Development and subsequent refinement of the inflammatory bowel disease questionnaire: a quality-of-life instrument for adult patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1999;28: S23-S27.
19. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70:439-444.
20. Jagannathan M, Hasturk H, Liang Y, et al. TLR cross-talk specifically regulates cytokine production by B cells from chronic inflammatory disease patients. J Immunol. 2009;183:7461-7470.
21. Mir A, Minguez M, Tatay J, et al. Elevated serum eotaxin levels in patients with inflammatory bowel disease. Am J Gastroenterol. 2002;97: 1452-1457.
22. Clutterbuck E, Shields JG, Gordon J, et al. Recombinant human interleukin 5 is an eosinophil differentiation factor but has no activity in standard human B cell growth factor assays. Eur J Immunol. 1987;17:1743-1750.
23. Wedemeyer J, Vosskuhl K. Role of gastrointestinal eosinophils in inflammatory bowel disease and intestinal tumours. Best Pract Res Clin Gastroenterol. 2008;22:537-549.
24. Mishra A, Hogan SP, Brandt EB, et al. Peyer's patch eosinophils: identification, characterization, and regulation by mucosal allergen exposure, interleukin-5, and eotaxin. Blood. 2000;96:1538-1544.
25. Jia GQ, Gonzalo JA, Hidalgo A, et al. Selective eosinophil transendothelial migration triggered by eotaxin via modulation of Mac-1/ICAM-1 and VLA-4/VCAM-1 interactions. Int Immunol. 1999;11:1-10.
26. Pabst O, Ohl L, Wendland M, et al. Chemokine receptor CCR9 contributes to the localization of plasma cells to the small intestine. J Exp Med. 2004;199:411-416.
27. Kunkel EJ, Kim CH, Lazarus NH, et al. CCR10 expression is a common feature of circulating and mucosal epithelial tissue IgA Ab-secreting cells. J Clin Invest. 2003;111:1001-1010.
28. Yamamura K, Adachi T, Masuda T, et al. Intracellular protein phosphorylation in eosinophils and the functional relevance in cytokine production. Int Arch Allergy Immunol. 2009;149(suppl 1):45-50.
29. Badewa AP, Heiman AS. Inhibition of CCL11, CCL24, and CCL26- induced degranulation in HL-60 eosinophilic cells by specific inhibitors of MEK1/MEK2, p38 MAP kinase, and PI 3-kinase. Immunopharmacol Immunotoxicol. 2003;25:145-157.
30. Kampen GT, Stafford S, Adachi T, et al. Eotaxin induces degranulation and chemotaxis of eosinophils through the activation of ERK2 and p38 mitogen-activated protein kinases. Blood. 2000;95:1911-1917.
31. Sanderson MP, Wex E, Kono T, et al. Syk and Lyn mediate distinct Syk phosphorylation events in FcvarepsilonRI-signal transduction: implications for regulation of IgE-mediated degranulation. Mol Immunol. 48:171-178.
32. Coats SR, Pham TT, Bainbridge BW, et al. MD-2 mediates the ability of tetra-acylated and penta-acylated lipopolysaccharides to antagonize Escherichia coli lipopolysaccharide at the TLR4 signaling complex. J Immunol. 2005;175:4490-4498.
33. Coats SR, Reife RA, Bainbridge BW, et al. Porphyromonas gingivalis lipopolysaccharide antagonizes Escherichia coli lipopolysaccharide at tolllike receptor 4 in human endothelial cells. Infect Immun. 2003;71:6799- 6807.
34. Lundahl J, Moshfegh A, Gronneberg R, et al. Eotaxin increases the expression of CD11b/CD18 and adhesion properties in IL5, but not fMLP-prestimulated human peripheral blood eosinophils. Inflammation. 1998;22:123-135.
35. Ganley-Leal LM, Mwinzi PN, Cetre-Sossah CB, et al. Correlation between eosinophils and protection against reinfection with Schistosoma mansoni and the effect of human immunodeficiency virus type 1 coinfection in humans. Infect Immun. 2006;74:2169-2176.
36. Mawhorter SD, Stephany DA, Ottesen EA, et al. Identification of surface molecules associated with physiologic activation of eosinophils. Application of whole-blood flow cytometry to eosinophils. J Immunol. 1996;156: 4851-4858.
37. Nopp A, Lundahl J, Hallden G. Quantitative, rather than qualitative, differences in CD69 upregulation in human blood eosinophils upon activation with selected stimuli. Allergy. 2000;55:148-156.
38. Plötz SG, Lentschat A, Behrendt H, et al. The interaction of human peripheral blood eosinophils with bacterial lipopolysaccharide is CD14 dependent. Blood. 2001;97:235-241.
39. Sundstrom P, Lundin SB, Nilsson LA, et al. Human IgA-secreting cells induced by intestinal, but not systemic, immunization respond to CCL25 (TECK) and CCL28 (MEC). Eur J Immunol. 2008;38:3327-3338.
40. Johansen FE, Baekkevold ES, Carlsen HS, et al. Regional induction of adhesion molecules and chemokine receptors explains disparate homing of human B cells to systemic and mucosal effector sites: dispersion from tonsils. Blood. 2005;106:593-600.
41. Hieshima K, Kawasaki Y, Hanamoto H, et al. CC chemokine ligands 25 and 28 play essential roles in intestinal extravasation of IgA antibodysecreting cells. J Immunol. 2004;173:3668-3675.
42. Raab Y, Fredens K, Gerdin B, et al. Eosinophil activation in ulcerative colitis: studies on mucosal release and localization of eosinophil granule constituents. Dig Dis Sci. 1998;43:1061-1070.
43. Lampinen M, Rönnblom A, Amin K, et al. Eosinophil granulocytes are activated during the remission phase of ulcerative colitis. Gut. 2005;54: 1714-1720.
44. Chen W, Paulus B, Shu D, et al. Increased serum levels of eotaxin in patients with inflammatory bowel disease. Scand J Gastroenterol. 2001; 36:515-520.
45. Forbes E, Smart VE, D'Aprile A, et al. T helper-2 immunity regulates bronchial hyperresponsiveness in eosinophil-associated gastrointestinal disease in mice. Gastroenterology. 2004;127:105-118.
46. Forbes E, Murase T, Yang M, et al. Immunopathogenesis of experimental ulcerative colitis is mediated by eosinophil peroxidase. J Immunol. 2004; 172:5664-5675.
47. Jeziorska M, Haboubi N, Schofield P, et al. Distribution and activation of eosinophils in inflammatory bowel disease using an improved immunohistochemical technique. J Pathol. 2001;194:484-492.
48. Pastor Rojo O, López San Román A, Albéniz Arbizu E, et al. Serum lipopolysaccharide-binding protein in endotoxemic patients with inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:269-277.
49. Aoki K. A study of endotoxemia in ulcerative colitis and Crohn's disease. II. Experimental study. Acta Med Okayama. 1978;32:207-216.
50. Amati L, Caradonna L, Leandro G, et al. Immune abnormalities and endotoxemia in patients with ulcerative colitis and in their first degree relatives: attempts at neutralizing endotoxin-mediated effects. Curr Pharm Des. 2003;9:1937-1945.
51. Pasternak BA, D'Mello S, Jurickova II, et al. Lipopolysaccharide exposure is linked to activation of the acute phase response and growth failure in pediatric Crohn's disease and murine colitis. Inflamm Bowel Dis. 2010; 16:856-869.
52. Ley RE, Turnbaugh PJ, Klein S, et al. Microbial ecology: human gut microbes associated with obesity. Nature. 2006;444:1022-1023.
53. Nagalingam NA, Lynch SV. Role of the microbiota in inflammatory bowel diseases. Inflamm Bowel Dis. 2012;18:968-984.
54. Hechtman DH, Cybulsky MI, Fuchs HJ, et al. Intravascular IL-8. Inhibitor of polymorphonuclear leukocyte accumulation at sites of acute inflammation. J Immunol. 1991;147:883-892.
55. Berrebi D, Languepin J, Ferkdadji L, et al. Cytokines, chemokine receptors, and homing molecule distribution in the rectum and stomach of pediatric patients with ulcerative colitis. J Pediatr Gastroenterol Nutr. 2003;37:300-308.
56. Jung YJ, Woo SY, Jang MH, et al. Human eosinophils show chemotaxis to lymphoid chemokines and exhibit antigen-presenting-cell-like properties upon stimulation with IFN-gamma, IL-3 and GM-CSF. Int Arch Allergy Immunol. 2008;146:227-234.
57. Liu LY, Jarjour NN, Busse WW, et al. Chemokine receptor expression on human eosinophils from peripheral blood and bronchoalveolar lavage fluid after segmental antigen challenge. J Allergy Clin Immunol. 2003; 112:556-562.
58. Coppi LC, Thomazzi SM, de Ayrizono ML, et al. Comparative study of eosinophil chemotaxis, adhesion, and degranulation in vitro in ulcerative colitis and Crohn's disease. Inflamm Bowel Dis. 2007;13:211-218.
59. O'Gorman MT, Jatoi NA, Lane SJ, et al. IL-1beta and TNF-alpha induce increased expression of CCL28 by airway epithelial cells via an NFkappaBdependent pathway. Cell Immunol. 2005;238:87-96.
60. Wang HB, Weller PF. Pivotal advance: eosinophils mediate early alum adjuvant-elicited B cell priming and IgM production. J Leukoc Biol. 2008; 83:817-821.
61. Chu VT, Fröhlich A, Steinhauser G, et al. Eosinophils are required for the maintenance of plasma cells in the bone marrow. Nat Immunol. 2011;12: 151-159.